NCT01657552View on ClinicalTrials.gov

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 1, 2012

Primary Completion Date

October 26, 2012

Study Completion Date

October 26, 2012

Conditions
Thrombocytopaenia
Interventions
DRUG

Eltrombopag

Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)

DRUG

Boceprevir

Each capsule contains 200 mg of Boceprevir (Dose 800 mg)

DRUG

Telaprevir

Each tablet contains 375 mg of Telaprevir (Dose 750 mg)

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01657552 - Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects | Biotech Hunter | Biotech Hunter